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The Incidence of Chronic Mesenteric Ischemia in the
Well-Defined Region of a Dutch Mesenteric Ischemia
Expert Center
Luke G. Terlouw, MD1,2, Mandy Verbeten3, Desire´e van Noord, MD, PhD4, Marjolein Brusse-Keizer, PhD5, Ruth R. Beumer, MD6,
Robert H. Geelkerken, MD, PhD7,8, Marco J. Bruno, MD, PhD1 and Jeroen J. Kolkman, MD, PhD3,9 Dutch Mesenteric
Ischemia Study Group
INTRODUCTION: This study aimed to determine the incidence of chronic mesenteric ischemia (CMI) and to examine the
influence of the etiological cause, location, and severity of a mesenteric artery stenosis on the
probability of having CMI.
METHODS: Aprospective database, containing the details of all patients with suspected CMI referred to a renowned
CMI expert center, was used. Patients residing within the expert centers’ well-defined region, between
January 2014 and October 2019, were included. CMI was diagnosed when patients experienced
sustained symptom improvement after treatment.
RESULTS: This study included 358 patients, 75 had a‡50%atherosclerotic stenosis of 1 vessel (CMI 16%), 96 of
2 or 3 vessels (CMI 81%), 81 celiac artery compression (CMI 25%), and 84 no stenosis (CMI 12%). In
total, 138 patients were diagnosed with CMI, rendering a mean incidence of 9.2 (95% confidence
interval [CI] 6.2–13.7) per 100,000 inhabitants. Atherosclerotic CMI was most common, with a mean
incidence of 7.2 (95% CI 4.6–11.3), followed by median arcuate ligament syndrome 1.3 (95% CI
0.5–3.6) and chronic nonocclusive mesenteric ischemia 0.6 (95% CI 0.2–2.6). The incidence of CMI
was highest in female patients (female patients 12.0 [95%CI 7.3–19.6] vs male patients 6.5 [95% CI
3.4–12.5]) and increased with age. CMI was more prevalent in the presence of a ‡70% atherosclerotic
single-vessel stenosis of the superior mesenteric artery (40.6%) than the celiac artery (5.6%).
DISCUSSION: The incidence of CMI is higher than previously believed and increases with age. Probability of CMI
seems highest in suspected CMI patients with multivessel disease or a ‡70% atherosclerotic single-
vessel superior mesenteric artery stenosis.
Clinical and Translational Gastroenterology 2020;11:e00200. https://doi.org/10.14309/ctg.0000000000000200
INTRODUCTION
Chronic mesenteric ischemia (CMI) is characterized by com-
plaints of postprandial pain and weight loss from the fear of
eating. CMI is the result of a compromised oxygen supply to the
gut and can be caused by occlusive mesenteric ischemia or non-
occlusive mesenteric ischemia (NOMI) (1). Occlusive CMI is
caused by stenosis or occlusion of $1 mesenteric artery, which
can be caused by atherosclerosis, vasculitis, or celiac artery (CA)
compression. The latter can result in median arcuate ligament
syndrome (MALS). Chronic NOMI is defined as CMI in the
absence of a mesenteric artery stenosis and is associated with
cardiac forward failure, pulmonary hypertension, severe chronic
obstructive pulmonary disease, hemodialysis, or vasospasms of
the mesenteric arteries (1–3).
The incidence of CMI is presumed to be very low, which may
result in insufficient awareness among clinicians and un-
derestimation of the magnitude of this disease. Atherosclerotic
mesenteric artery stenoses are the most common cause of CMI
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and are frequently found in the general population. The preva-
lence of atherosclerotic mesenteric artery stenosis is 6%–29% and
increases with age (1,4,5). Despite the high prevalence of mes-
enteric artery stenosis, only a minority will result in ischemia and
become symptomatic because the gut is protected against ische-
mia by an extensive collateral circulation. Previous retrospective
studies report higher clinical success rates of revascularization in
patients with$2 stenoticmesenteric arteries than in patientswith
a single-vessel mesenteric artery stenosis because the collateral
circulation is more likely to be compromised in patients with
multivessel disease (6–9). Experts believe that the risk of de-
veloping CMI also depends on the etiological cause of the stenosis
(e.g., atherosclerosis andCA compression) and the location of the
stenosis (i.e., CA, superior mesenteric artery [SMA] and inferior
mesenteric artery); however, conclusive evidence supporting this
belief is unavailable (10).
The purpose of this study was to determine the incidence of
CMI and to examine the influence of the etiological cause, loca-
tion, and severity of a mesenteric artery stenosis on the occur-
rence of CMI in symptomatic patients with suspected CMI.
METHODS
Study design
This cohort study is based on a prospective database of patients
analyzed for suspectedmesenteric ischemia inMedisch Spectrum
Twente, a mesenteric ischemia expert center. Data regarding
medical history, presenting symptoms, diagnostic tests, severity
of mesenteric artery stenosis, diagnosis, treatment, and follow-up
were collected and pseudoanonymized with a unique code. In-
clusion in the database started in January 2014; follow-up data
until October 2019 was used in the current study. Informed
consent was obtained from all participating patients. The local
medical research ethics committee decided that the Medical Re-
search InvolvingHuman Subjects Act does not apply to this study
(K19-52). The investigators complied with the Helsinki declara-
tion on research ethics. The STROBE checklist for cohort studies
was used to write this study (11).
Study cohort
All patients analyzed for suspected CMI living within the region of
the study center were included in the study. Patients not residing
within the region and patients diagnosed with acute mesenteric
ischemia, without preceding symptoms of CMI, were excluded. The
study center is located in a rural area and has a well-defined region
with approximately 263,500 inhabitants—approximately 133,400
male and 130,100 female patients. The study center is a national
mesenteric ischemia expert center, analyzing and treating patients
with mesenteric ischemia from all over the country and is the re-
gion’s only expert center. For several decades, the study center has
made a great effort to raise awareness for CMI within their region.
The “Dutch Hospital Data” database, containing data of the Dutch
health reimbursement system, was searched to verify whether pa-
tients treated for mesenteric ischemia residing within the region
presented in the study center (used diagnosis code DBC 405, is-
chemia of the intestine). During the study period, adherence of the
region’smesenteric ischemia patients to the study centerwas 98.8%.
Diagnostic workup and diagnosis of CMI
A standardized diagnostic workup was performed in all patients
with suspected CMI and consisted of assessment of symptoms,
imaging of the mesenteric arteries (duplex ultrasound or
computed tomography angiography), and, when indicated, as-
sessment ofmucosal ischemia by gastrointestinal tonometry (12).
The results of the workup were discussed by an experienced
multidisciplinary expert team consisting of gastroenterologists,
interventional radiologists, and vascular surgeons. Treatment
decisions were based on a consensus diagnosis of CMI, which was
established when CMI was deemed to be a likely explanation for
the presenting symptoms, in the absence of a possible alternative
diagnosis (12). A definitive diagnosis of CMI was established
when symptoms improved or resolved at 3 months after re-
vascularization or in case of chronicNOMIduring treatmentwith
a vasodilator. Patients with a consensus diagnosis of no CMI or
those initially labeled as CMI, but without improvement of
symptoms after treatment, were classified as non-CMI.
Primary outcome
The primary outcome is the annual incidence rate of all-cause
CMI. All-cause CMI is defined as the sum of the incidences of the
definitive diagnoses of atherosclerotic CMI, MALS, and chronic
NOMI. Incidence rates are shown per 100,000 inhabitants. The
number of inhabitants residing within the region on the first of
January of each year was retrieved from Statistics Netherlands
(CBS) and used to calculate the annual incidence. Because data of
2019 had been collected until October, an expected number of
atherosclerotic CMI, MALS, and chronic NOMI patients was
calculated based on the number of patients presenting in the
month of January until October.
Secondary outcomes
Four secondary outcomes were formulated. First, the incidence
rate specified per etiological cause, i.e., atherosclerotic CMI,
MALS, and chronic NOMI, including stratification by age and
sex. Second, the differences in cause, location, and number of
stenotic mesenteric arteries between patients with a definitive
diagnosis of CMI and non-CMI. The grade of stenosis was cal-
culated according to the North American Symptomatic Carotid
EndarterectomyTrial method, which is oneminus the ratio of the
smallest diameter at the level of the occlusive lesion and the di-
ameter of a normal part of artery distal to the stenosis converted
to percent (13). A stenosis of ,50% was labeled as no stenosis,
$50% and ,70% as an intermediate stenosis, and $70% as a
severe stenosis. Third, the clinical success rates of re-
vascularization in patients with atherosclerotic CMI and patients
with MALS. Clinical success was defined as sustained improve-
ment or disappearance of symptoms after successful re-
vascularization. Fourth, the survival, starting at diagnosis, of
patients with a definitive diagnosis of atherosclerotic CMI, a de-
finitive diagnosis of MALS, and non-CMI.
Statistical analysis
Statistical analyses were performed with R version 3.5.3
(R Foundation for Statistical Computing, Vienna, Austria) using
packages epiR, survival, and GGAlly. Numerical baseline char-
acteristics were not equally distributed and are, therefore, shown
asmedian and interquartile ranges (IQR). Baseline characteristics
of patients with CMI and patients without CMI were compared
using x2 tests for categorical variables andWilcoxon signed-rank
tests for numerical variables. Overall and age-specific and sex-
specific incidence rates were based on the number of cases with
CMI and each etiological cause and were expressed as number of
cases per 100,000 inhabitants. The reported overall incidence
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rates comprise the mean incidence over the 6-year study period.
Incidence rates and confidence intervals (CIs) were calculated
using R package epiR, the used method was “prop.single.” The
relationship between the location and number of mesenteric ar-
tery stenoses and a definitive diagnosis of CMIwas assessed by the
x2 or fisher exact tests. Survival of patients without CMI, patients
with atherosclerotic CMI, and patients with MALS was assessed
by the Kaplan-Meier method and compared using the logrank
test. The hazard ratio (HR), with 95% CI of mortality in athero-
sclerotic CMI patients and non-CMI patients with an athero-
sclerotic mesenteric artery stenosis, was calculated using an
univariate cox proportional hazard regression model.
RESULTS
Patient characteristics
During the study period, 2,188 patients with suspected CMI were
analyzed at the study center, of whom 358 (16.4%) resided within
the region of the study center. A definitive diagnosis of CMI was
established in 138 (38.5%) of the regional patients, the remaining
220 patients were classified as non-CMI. Comparison of baseline
characteristics of both groups revealed that patients with CMI
were significantly older (median [IQR] CMI 72 [55–79] vs non-
CMI 58 [34–73]; P , 0.001) and had a significantly shorter du-
rations of follow-up (median [IQR] CMI 19 [6–36] months vs
non-CMI 30 [12–48]months;P, 0.001). The cardiovascular risk
factors dyslipidemia, hypertension, and history of cardiovascular
disease were more frequently present in patients with CMI, P ,
0.001 (Table 1).Of the reported presenting symptoms, weight loss
and an adapted eating pattern were significantlymore frequent in
patients with CMI, whereas weight and body mass index were
significantly lower in patients with CMI than in patients without
CMI. The subgroup of patients withMALShad amedian age of 28
years (IQR 23–43), and 80% were female patients.
Incidence rates
Table 2 shows that the incidence of all-cause CMI increased from
7.2 (95% CI 4.6–11.3) per 100,000 inhabitants in 2014 to up to
11.1 (95% CI 7.8–15.9) in 2019. Resulting in a mean incidence of
all-cause CMI of 9.2 (95% CI 6.2–13.7). The mean incidence of
atherosclerotic CMI was 7.3 (95% CI 4.6–11.3) and showed an
increasing trendwith an incidence of 4.9 (95%CI 2.9–8.4) in 2014
increasing up to 10.1 (95% CI 6.9–14.7) in 2019 (Figure 1). The
incidence of MALS (mean incidence [95% CI] 1.3 [0.5–3.6]) and
chronic NOMI (mean incidence [95% CI] 0.6 [0.2–2.6])
Table 1. Baseline characteristics
Baseline characteristic
All patients CMI Non-CMI
P value(N 5 358) (N5 138) (N 5 220)
Female sex 60.3% 63.8% 58.2% 0.347
Age 64 (43–76) 72 (55–79) 58 (34–73) ,0.001
Follow-up (mo) 26 (10–43) 19 (6–36) 30 (12–48) ,0.001
Risk factors
Cardiovascular disease 35.5% 48.6% 27.3% ,0.001
Peripheral artery disease 20.1% 31.2% 13.2% ,0.001
Coronary artery disease 23.2% 31.9% 17.7% 0.003
Cerebrovascular disease 10.1% 12.3% 8.6% 0.344
Dyslipidemia 22.6% 34.1% 15.5% ,0.001
Hypertension 34.4% 47.8% 25.9% ,0.001
Diabetes 15.4% 18.1% 13.6% 0.320
Family history of CVD 7.0% 6.5% 7.3% 0.953
Smoking 70.6% 78.2% 65.6% 0.067
Pack years 29 (10–40) 30 (11–46) 22 (10–40) 0.807
Presenting symptoms
Weight loss 63.5% 75.8% 54.9% 0.002
Weight (kg) 66 (56–78) 62 (55–74) 68 (57–82) 0.005
Body mass index 23 (20–26) 22 (19–26) 23 (20–27) 0.049
Abdominal pain 84.6% 85.1% 84.2% 0.980
Duration abdominal pain (mo) 6 (2–12) 6 (2–12) 6 (2–12) 0.497
Postprandial abdominal pain 62.1% 65.7% 59.7% 0.419
Exercise induced abdominal pain 50.0% 48.7% 50.8% 0.886
Adapted eating pattern 68.0% 76.9% 62.1% 0.044
Nausea 62.0% 62.6% 61.6% 0.984
CMI, chronic mesenteric ischemia; CVD, cardiovascular disease.
American College of Gastroenterology Clinical and Translational Gastroenterology
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remained relatively stable. Stratification for sex showed a higher
mean incidence of all-cause CMI, atherosclerotic CMI, and
MALS in female patients (Figure 2a). Stratification for age showed
that the mean incidence of all-cause CMI and atherosclerotic
CMI increased with age, whereas the mean incidence of MALS
decreased with age (Figure 2b).
Cause and severity of mesenteric artery stenosis in patients with
suspected CMI
One hundred ninety of the 358 patients (53%) with suspected
CMI had $1 atherosclerotic mesenteric artery stenosis on im-
aging. CA compression was present in 81 patients (23%), a
combination of CA compression and atherosclerosis was present
in 3 patients (1%), and the remaining 84 (23%) patients had no
stenosis on imaging. Table 3 shows that most patients with an
atherosclerotic stenosis had a definitive diagnosis ofCMI (55.3%).
CMI was present in 12 of 75 patients (16.0%) with a single-vessel
atherosclerotic stenosis, 67 of 85 patients (78.8%) with 2 ath-
erosclerotic mesenteric artery stenoses, and 26 of 30 patients
(86.7%)with 3 atheroscleroticmesenteric artery stenoses. Twenty
of 81 patients (24.7%) with CA compression was diagnosed with
MALS. Chronic NOMI was diagnosed in 10 of 84 patients
(11.9%) without a mesenteric artery stenosis.
Grading of stenosis severity was available in a subgroup of 166
patients with an atherosclerotic mesenteric artery stenosis, of
whom 75 had a definitive diagnosis of CMI. Table 4 shows that
CMI was most frequent in patients with a severe stenosis of both
CA and SMA (87.3%). The proportion of atherosclerotic CMI
patients with a severe CA stenosis and no SMA stenosis is low
(5.6%). By contrast, CMI was more frequent in patients with a
severe SMA stenosis and no CA stenosis (40.6%).
Clinical success
One hundred nineteen patients underwent a revascularization pro-
cedure. Hundred patients underwent revascularization of an ath-
erosclerotic stenosis, the remaining 19 patients underwent an
endoscopic retroperitonealCArelease forMALS.Theclinical success
rate of revascularizationwas91.9% inpatientswith anatherosclerotic
stenosis (Table 5). Patients with multivessel atherosclerotic stenoses
had a higher clinical success rate (95.4%) than patients with a single-
vessel atherosclerotic stenosis (69.2%).The clinical success rate ofCA
release was 89.5%. Revascularization was not performed in 19 pa-
tients with a consensus diagnosis of atherosclerotic CMI or MALS.
Reasons not to revascularize were severe comorbidities in 9 patients,
refusal of treatment in 8 patients, and death before revascularization
in 2 patients, of whom 1 died of acute on CMI.
Survival
Sixty-four patients (17.9%) referred for suspected CMI died
during follow-up (38 CMI vs 26 non-CMI). Mesenteric ischemia
Table 2. Annual incidence rates of CMI and the annual number of new CMI cases
No. of patients 2014 2015 2016 2017 2018 2019a Mean
Referred for suspected CMI 53 63 61 68 65 64 62.3
All-cause CMI 19 25 21 27 24 29 24.2
Atherosclerotic CMI 13 17 15 23 20 26 19.0
MALS 2 6 4 2 4 3 3.5
Chronic NOMI 4 2 2 2 0 0 1.7
Incidence rates per 100,000
(95% CI) 2014 2015 2016 2017 2018 2019a Mean
All-cause CMI 7.2 (4.6–11.3) 9.5 (6.4–14.0) 8.0 (5.2–12.2) 10.3 (7.1–14.9) 9.1 (6.1–13.6) 11.1 (7.8–15.9) 9.2 (6.2–13.7)
Atherosclerotic CMI 4.9 (2.9–8.4) 6.5 (4.0–10.3) 5.7 (3.5–9.4) 8.7 (5.8–13.1) 7.6 (4.9–11.7) 10.1 (6.9–14.7) 7.3 (4.6–11.3)
MALS 0.8 (0.2–2.8) 2.3 (1.0–5.0) 1.5 (0.6–3.9) 0.8 (0.2–2.8) 1.5 (0.6–3.9) 1.0 (0.3–3.2) 1.3 (0.5–3.6)
Chronic NOMI 1.5 (0.6–3.9) 0.8 (0.2–2.8) 0.8 (0.2–2.8) 0.8 (0.2–2.8) 0.0 0.0 0.6 (0.2–2.6)
CI, confidence interval; CMI, chronic mesenteric ischemia; MALS, median arcuate ligament syndrome; NOMI, non-occlusive mesenteric ischemia.
aPredicted number of patients based on first 9 months.
Figure1. Incidence rates of all-causeCMI, atherosclerotic CMI,MALS, and
chronic NOMI. CMI, chronic mesenteric ischemia; MALS, median arcuate
ligament syndrome; NOMI, nonocclusive mesenteric ischemia.
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was the cause of death in 9 CMI patients, of whom8 patients had
multivessel stenoses and 1 patient had no stenosis. No non-CMI
patients died of mesenteric ischemia. Survival analysis of all
patients showed that the mortality at 24 months of follow-up
was 36.6% (95% CI 24.7%–46.6%) in patients with CMI, 0%
(95% CI 0%–0%) in patients with MALS, and 10.8% (95% CI
6.3%–15.1%) in patients without CMI (Figure 3). Survival of
patients with atherosclerotic CMI was significantly worse than
survival of patients without CMI and patients with MALS.
Subgroup analysis of patients with an atheroscleroticmesenteric
artery stenosis showed a significantly higher risk of mortality in
patients with atherosclerotic CMI (HR [95% CI] 2.57
[1.38–4.73]; P 5 0.002).
DISCUSSION
This study is the first to report the incidence of all-cause CMI,
encompassing atherosclerotic CMI, MALS, and chronic NOMI.
The observed incidence of all-cause CMI of at least 9.2 per
100,000 inhabitants overrules the notion that CMI is a rare dis-
ease. Furthermore, this study suggests that the probability of
developing CMI is influenced by the nature of amesenteric artery
stenosis (atherosclerotic or compression) and single-vessel or
multivessel involvement.
For decades, CMI has been assumed to be a rare disease. The
current study sheds a different light on this widespread mis-
conception (1). In this well-defined cohort, all-cause CMI was
found to have an incidence of 9.2 per 100,000 inhabitants, which
approximates the incidence of Crohn’s disease (10.9 per
100,000)—established over a 20-year period in a Dutch cohort
(14). Examining the incidence of other vascular diseases, the in-
cidence of all-cause CMI is higher than the incidence of ruptured
abdominal aortic aneurysms (7.0 per 100.000) (15) and almost
twice as high as the incidence of occlusive acute mesenteric is-
chemia (4.5–5.4 per 100,000) (16). This study reports a higher
incidence of atherosclerotic CMI and MALS in female patients
and confirms the female predisposition reported by other studies
(1,17,18). The observation that the incidence of atherosclerotic
CMI increases with age is plausible because the prevalence of
mesenteric artery stenosis has been reported to increase with age
as well (4,5). These new data emphasize the urgent need to im-
prove awareness about the existence of CMI and its clinical
burden including severe symptoms, loss of quality of life, and
increased mortality among patients with atherosclerotic CMI.
Importantly, clinicians should be educated about the fact that in
over 90% of patients with CMI, symptom improvement can be
reached.
Interestingly, the rise in the incidence of all-cause CMI during
the study period was exclusively explained by an increasing
number of patients diagnosed with atherosclerotic CMI. The
incidence ofMALS and chronicNOMI remained relatively stable.
This increase may signify a true increase in the incidence of
atherosclerotic CMI related to an increasing prevalence of
Figure 2. (a) Mean incidence rates with 95%CI of all-cause CMI, atherosclerotic CMI, MALS, and chronic-NOMI stratified by sex. (b) Mean incidence rates
with 95% CI of all-cause CMI, atherosclerotic CMI, MALS, and chronic-NOMI stratified by age. CI, confidence interval; CMI, chronic mesenteric ischemia;
MALS, median arcuate ligament syndrome; NOMI, non-occlusive mesenteric ischemia.
Table 3. Cause of mesenteric artery stenosis in patients with
suspected CMI stratified by a definitive diagnosis of CMI
Cause mesenteric artery stenosis
CMI Non-CMI
% IschemiaN 5 138 N 5 220
No stenosis 10 74 11.9
Atherosclerosis 105 85 55.3
1 vessel atherosclerosis 12 63 16.0
2 vessel atherosclerosis 67 18 78.8
3 vessel atherosclerosis 26 4 86.7
Atherosclerosis and CA compression 3 0 100
CA compression 20 61 24.7
CA, celiac artery; CMI, chronic mesenteric ischemia.
American College of Gastroenterology Clinical and Translational Gastroenterology
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cardiovascular risk factors in an aging western population be-
cause the prevalence of atherosclerotic mesenteric artery stenosis
also increases with age (4,5). However, increased awareness for
atherosclerotic CMI could be another likely explanation for this
increase in CMI incidence.
Experts in the field of CMI have always claimed that the se-
verity, location, and cause of a mesenteric artery stenosis are
important denominators that influence the probability of having
CMI; but, evidence to support this claim was limited to circum-
stantial evidence (10). The importance of the cause of a mesen-
teric artery stenosis is suggested by the relatively high proportion
of CMI in symptomatic patients with an atherosclerotic stenosis
(55.3%). The proportion of MALS in patients with symptoms
suggestive of CMI in combination with a mesenteric artery ste-
nosis caused by CA compression was 24.7%. This indicates that
alternative diagnoses should be considered and excluded because
MALS is not the cause of the symptoms in 75.3% of the patients
with CA compression. CMI was most frequently present in
symptomatic patients withmultivessel atheroscleroticmesenteric
artery stenoses (81%), compared with only 16% in symptomatic
patients with an atherosclerotic stenosis of a single mesenteric
artery. In symptomatic patients with a single-vessel atheroscle-
rotic mesenteric artery stenosis, the location of the stenosis
seemed of importance because CMI was present in 40.6% of the
patients with a severe SMA stenosis, but in only 5.6% of the
patients with a severe CA stenosis. The probability of CMI seems,
therefore, highest in symptomatic patients with eithermultivessel
mesenteric artery stenoses or a single-vessel atherosclerotic SMA
stenosis.
Reported clinical success rates of revascularizations in
multivessel disease are excellent (90%–100%) (6,7,9). The
current study supports these findings with a clinical success
rate of 95.4% in patients with multivessel disease. A lower
clinical success rate of 73% is reported in patients with single-
vessel atherosclerotic CMI (8). Based on a relatively low
number of patients, the current study shows a comparable
clinical success rate of 69.2%. A systematic review reporting on
400 patients treated by a CA release showed sustained clinical
success in 80% of patients (19). The slightly higher reported
clinical success rate of CA release of 89.5% in the current study
might be explained by some statistical variation because of the
relatively low number of included cases or a more appropriate
patient selection because of the use of gastrointestinal to-
nometry (20).
In the literature, definitions for a mesenteric artery stenosis
range from 50% to 70% but are still a topic of discussion
(7,8,21–23). This study suggests that a $70% cutoff would be
appropriate in patients with single-vessel disease because the
probabilities of CMI in isolated intermediate stenosis were 0%
and 10% for the CA and SMA, respectively. A$70% cutoff could
reduce the risk of overtreatment, which is currently 27–31% (8). A
cutoff of $50% seems appropriate in patients with a stenosis of
bothCA and SMAbecause the probability of CMIwas 83% in this
group of patients. Overtreatment is less of an issue inmulti-vessel
disease of CA and SMA, since clinical success ranges from 90% to
100% (6,7,9).
Figure 3 shows the survival rates of patients with MALS,
patients with atherosclerotic CMI, and patients without CMI.
The observed differences in mortality might be explained by
differences in disease mechanism and baseline characteristics.
The 0% mortality rate of MALS is a logical consequence of the
younger age of these patients (median age 28 years) and the fact
Table 4. Severity of atherosclerotic CA and SMA stenosis and
presence of CMI
SMA stenosis
£50% 51%–70% >70%
N % CMI N % CMI N % CMI
CA stenosis
#50% 25 12.0 10 10.0 32 40.6
51%–70% 12 0.0 2 0.0 8 100.0
.70% 18 5.6 4 25.0 55 87.3
CA, celiac artery; CMI, chronic mesenteric ischemia; N, number of CMI and
non-CMI patients with a stenosis; SMA, superior mesenteric artery.
Table 5. Clinical success of mesenteric artery revascularization
Cause mesenteric artery stenosis
Clinical success
% (N)
Atherosclerotic stenosis 91.9 (91)
Single-vessel atherosclerotic stenosis 69.2 (9)
Multivessel atherosclerotic stenosis 95.4 (83)
CA artery compression 89.5 (17)
CA, celiac artery.
Figure 3. Kaplan-Meyer survival analysis of patients without CMI, patients
with atherosclerotic CMI, and patients with MALS. *Statistically significant
difference in survival between groups. CMI, chronic mesenteric ischemia;
MALS, median arcuate ligament syndrome.
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that the cause of this disease is mechanical, i.e., local CA com-
pression, and not a systemic disease. Mortality at the 24-month
follow-up was 36.6% in the atherosclerotic CMI population and
10.8% among patients without CMI. A previous study com-
paring mortality in patients with atherosclerotic CMI with the
expected mortality in the general population, using age- and
sex-specific mortality rates, reported an increased standardized
mortality risk of 3.55 in patients with CMI, supporting the
findings of the current study (24). The higher mortality in
atherosclerotic CMI could be due to the systemic nature of
atherosclerosis because atherosclerosis also affects other vas-
cular beds. However, the currently reported subgroup analysis
in patients with an atherosclerotic mesenteric artery stenosis
showed a significantly increased mortality risk in patients with
atherosclerotic CMI compared to patients without CMI (HR
2.57). The increased mortality could be due to CMI or more
extensive and severe atherosclerosis in patients with CMI, but a
detailed cause of death was not available for all deceased pa-
tients. Additional studies are, therefore, needed to confirm these
results and examine whether the cause of death is related to
cardiovascular events.
This study has several limitations inherent to database
studies. First, incidence rates are based on a relatively limited
number of patients with CMI presenting in a single expert
center. The number of missed CMI cases seems low because
adherence of the regional patients with CMI to the study center
approximated 100%. Underestimation of the true incidence of
all-cause CMI is, however, still probable because limited
knowledge and awareness among general practitioners and
clinicians is likely to result in underdiagnosing of CMI patients.
Second, the outcomes regarding clinical success rates, location,
and cause of mesenteric artery stenosis are based on limited
numbers of patients, which is caused by the epidemiological
nature of the study, restricting patient inclusion to residents of
the catchment area of the expert center. Despite the limitations,
this study provides a valuable approximation of the incidence
rates of CMI.
In conclusion, the estimated incidence of CMI of 9.2 per
100,000 is higher than previously estimated and comparable with
some other well-known gastrointestinal diseases such as Crohn’s
disease. Its incidence shows an increasing trend that seemsmainly
attributable to atherosclerotic CMI. Probability of CMI seems
highest in suspected patients with CMI with multivessel disease.
The minimally relevant percentage stenosis to develop CMI
seems 70% for single-vessel stenosis, whereas in multivessel dis-
ease a 50% stenosis already suffices.
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Study Highlights
WHAT IS KNOWN
3 CMI is a debilitating disease with an unknown incidence.
3 Asymptomatic mesenteric artery stenoses are frequently
observed in the general population.
WHAT IS NEW HERE
3 The incidence of CMI is 9.2 per 100,000 inhabitants (12.0 in
women and 6.5 in men).
3 CMI is most common in symptomatic patients with
atherosclerotic multivessel disease.
3 A SMA stenosis seems of greater clinical relevance than a CA
stenosis.
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